[
  {
    "ts": null,
    "headline": "Amneal Announces U.S. FDA Approval of Cyclosporine Ophthalmic Emulsion 0.05%",
    "summary": "Approval underscores Amneal’s advanced sterile manufacturing capabilities and expansion within complex ophthalmic therapies; Launch expected in Q1 2026 BRIDGEWATER, N.J., Dec. 01, 2025 (GLOBE NEWSWIRE) -- Amneal Pharmaceuticals, Inc. (“Amneal” or the “Company”) (NASDAQ: AMRX) today announced the U.S. Food and Drug Administration (FDA) has approved the Company’s cyclosporine ophthalmic emulsion 0.05%, a sterile, preservative-free formulation supplied in single-use vials. The product is the generi",
    "url": "https://finnhub.io/api/news?id=705974f16c37bec62ede219d3c46f85acb9a8c2c5cffc29dc32d735c7f140166",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1764622860,
      "headline": "Amneal Announces U.S. FDA Approval of Cyclosporine Ophthalmic Emulsion 0.05%",
      "id": 137658943,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ABBV",
      "source": "Yahoo",
      "summary": "Approval underscores Amneal’s advanced sterile manufacturing capabilities and expansion within complex ophthalmic therapies; Launch expected in Q1 2026 BRIDGEWATER, N.J., Dec. 01, 2025 (GLOBE NEWSWIRE) -- Amneal Pharmaceuticals, Inc. (“Amneal” or the “Company”) (NASDAQ: AMRX) today announced the U.S. Food and Drug Administration (FDA) has approved the Company’s cyclosporine ophthalmic emulsion 0.05%, a sterile, preservative-free formulation supplied in single-use vials. The product is the generi",
      "url": "https://finnhub.io/api/news?id=705974f16c37bec62ede219d3c46f85acb9a8c2c5cffc29dc32d735c7f140166"
    }
  },
  {
    "ts": null,
    "headline": "If You Invested $10K In AbbVie Stock 10 Years Ago, How Much Would You Have Now?",
    "summary": "AbbVie Inc. (NYSE:ABBV) engages in the research and development, manufacture, and sale of medicines and therapies worldwide. It is set to report its Q4 2025 earnings on Jan. 30. Wall Street analysts expect the company to post EPS of $3.36, up from ...",
    "url": "https://finnhub.io/api/news?id=c678fe35ee2343c8e8ee2e3105edf9fd8524786de96396c418693801d70941ec",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1764594066,
      "headline": "If You Invested $10K In AbbVie Stock 10 Years Ago, How Much Would You Have Now?",
      "id": 137658945,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ABBV",
      "source": "Yahoo",
      "summary": "AbbVie Inc. (NYSE:ABBV) engages in the research and development, manufacture, and sale of medicines and therapies worldwide. It is set to report its Q4 2025 earnings on Jan. 30. Wall Street analysts expect the company to post EPS of $3.36, up from ...",
      "url": "https://finnhub.io/api/news?id=c678fe35ee2343c8e8ee2e3105edf9fd8524786de96396c418693801d70941ec"
    }
  },
  {
    "ts": null,
    "headline": "AbbVie: Increased Outlook For 2025 And Expansions Merit Continued \"Strong Buy\" Rating",
    "summary": "Discover why AbbVie (ABBV) is a strong buy with expanding immunology, neuroscience, and oncology pipelines.",
    "url": "https://finnhub.io/api/news?id=cd344b45351b5568fb3d4c58324967399568fd6ee1adbe6e67322c5ec346dc6d",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1764568505,
      "headline": "AbbVie: Increased Outlook For 2025 And Expansions Merit Continued \"Strong Buy\" Rating",
      "id": 137651736,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2247731311/image_2247731311.jpg?io=getty-c-w1536",
      "related": "ABBV",
      "source": "SeekingAlpha",
      "summary": "Discover why AbbVie (ABBV) is a strong buy with expanding immunology, neuroscience, and oncology pipelines.",
      "url": "https://finnhub.io/api/news?id=cd344b45351b5568fb3d4c58324967399568fd6ee1adbe6e67322c5ec346dc6d"
    }
  }
]